Paul La Rosée - Concepedia

Author

Paul La Rosée

Also Known As

P La Rosée, P. La Rosee, P. La Rosée, P. La Rosée, P. Larosee, P., LaRosée, P.L. Rosée, PLa Rosée, Paul La Rosee, Paul La Roseé

216

Publications

10.1K

Citations

H-Index

Concepts

All Affiliations

Jena University Hospital Heidelberg University Schwarzwald-Baar Klinikum University Hospital Heidelberg University Medical Center Hamburg-Eppendorf

About

Paul La Rosée is an author at Jena University Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2.5K
2	Cell Biology	9	9	1.2K
3	Health Sciences	4	4	423
4	Biochemistry	2	2	62
5	Natural Sciences	1	1	36

Paul La Rosée

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults Paul La Rosée, AnnaCarin Horne, Melissa Hines, Blood	2019	997
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Andreas Hochhaus, Sebastian Kreil, A. Corbin, Leukemia ChromatinGenome InstabilityCell DivisionCytogeneticsChromatin Remodeling	2002	900
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, The Lancet Haematology	2016	582
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, The Lancet Haematology Neuro-oncologyRadiation OncologyLymphoid NeoplasiaTransplantationCell Therapy	2017	364
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Amie S. Corbin, Paul La Rosée, Eric P. Stoffregen, Blood	2003	314
Lack of clinical efficacy of imatinib in metastatic melanoma Selma Ugurel, Ralf Hildenbrand, A Zimpfer, British Journal of Cancer	2005	241
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation F. La Rosée, Hinrich Bremer, Iris Gehrke, Leukemia	2020	240
Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, Journal of Clinical Oncology	2018	238
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma Christine Dierks, Jochen Seufert, Konrad Aumann, Thyroid	2021	225

Page 1